Pivot Holding

Pivot Holding LLC is a biotechnology company that serves as the successor in interest to Sphaera Pharma, inheriting its portfolio of therapeutic assets and drug discovery platform. The company is primarily focused on the development of novel prodrugs of established protein kinase inhibitors to improve safety, efficacy, and delivery. Its lead asset, IKT-001 (a prodrug of imatinib), is currently being advanced in Phase 3 clinical trials for Pulmonary Arterial Hypertension (PAH) through a strategic collaboration and settlement agreement with Inhibikase Therapeutics. Pivot Holding maintains significant intellectual property rights and milestone-based interests in a pipeline targeting neurodegenerative and rare diseases.